Fluid Filled Lung Oxygenation Assistance Trial (FFLOAT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03041740|
Recruitment Status : Active, not recruiting
First Posted : February 3, 2017
Last Update Posted : April 8, 2021
|Condition or disease||Intervention/treatment||Phase|
|Bronchopulmonary Dysplasia||Drug: Perfluorooctyl Bromide||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study to Evaluate the Safety of Perflurooctylbromide (PFOB) Partial Liquid Ventilation (PLV) for Up to 10 Days in Neonates With Severe Bronchopulmonary Dysplasia (BPD)|
|Actual Study Start Date :||June 27, 2017|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||April 2022|
No Intervention: Usual Care (Control) Group
Control subjects will be treated as per standard of care for preterm infants with BPD.
Active Comparator: Perfluorooctylbromide (PFOB) Group
Subjects in the PFOB group will be administered an initial PFOB treatment dose of 2.5 mL/kg and up to a total intra-pulmonary volume of 25 mL/kg for up to 10 days.
Drug: Perfluorooctyl Bromide
Subjects in the PFOB group will receive PFOB partial liquid ventilation instilled via side port of endotracheal tube (2.5 mL/kg/day) across 10 treatment days.
Other Name: Perflubron
- Sustained oxygen desaturations for greater than ten minutes without response to increased oxygen therapy [ Time Frame: Day 5, Day 10 ]Incidence of sustained (greater than 10 minutes) oxygen desaturation events without response to increased oxygen therapy. These incidences will be measured by a continuous non-invasive percutaneous oxygen saturation monitor.
- Persistent hypotension without response to volume expansion and/or inotropic therapy [ Time Frame: Day 5, Day 10 ]Incidence of persistent hypotension without response to volume expansion and/or inotropic therapy. Hypotension is a decrease in systolic blood pressure deemed significant by clinical staff. Measurement will be performed with a standard intensive care unit blood pressure cuff.
- Change in number of major mucus plugging events [ Time Frame: Day 5, Day 10 ]Incidence of airway obstruction of the endotracheal tube, as indicated by decreased chest movement during mechanical ventilation, need for increased ventilator pressure, and/or elevation of carbon dioxide levels in the blood. Mucus plugs are confirmed by endotracheal suctioning.
- Incidence of pneumothorax or pleural effusion with PFOB [ Time Frame: Day 5, Day 10 ]Incidence of pneumothorax in the child will be measured by transillumination of the chest and confirmed by chest x-ray.
- Number of participants with sustained hypercapnia (elevated carbon dioxide in the blood, greater than 95 mmHg, for over four hours). [ Time Frame: Day 5, Day 10 ]Hypercapnia will be measured with blood tests and/or cutaneous carbon dioxide monitor.
- Change in fraction of inspired oxygen (FiO2) [ Time Frame: Day 5, Day 10 ]Fraction of inspired oxygen is the percentage of oxygen that the patient is receiving for his or her lung disease. An FiO2 of 0.21 is room air oxygen and 1.00 is 100% oxygen. The higher the FiO2, the more severe the respiratory disease.
- Change in ventilator mean airway pressure (MAP) [ Time Frame: Day 5, Day 10 ]Mean airway pressure (MAP) is the average amount of airway pressure supplied to the lungs throughout a breath. Higher MAP indicates more severe disease.
- Change in Respiratory Severity Score (MAP x FiO2) [ Time Frame: Day 5, Day 10 ]Respiratory Severity Score (RSS) is a scale computed as the Mean Airway Pressure (MAP) multiplied by the Fraction of Inspired Oxygen (FiO2). Clinically, the scale range will often lie between 1 and 10, with higher numbers indicating more severe disease. The RSS can theoretically reach a score as high as 30-35.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03041740
|United States, Pennsylvania|
|Children's Hospital of Philadelphia|
|Philadelphia, Pennsylvania, United States, 19104|
|Principal Investigator:||William Fox, MD||Children's Hospital of Philadelphia|